EBNA1 expression in a lung transplant recipient with hypocomplementemic urticarial vasculitis syndrome

Journal of Medical Virology

Volumn 79, Issue 7, 2007, Pages 963-969

  Berggren, Malin Å M ^a   Heinlen, Latisha ^b   Isaksson, Åsa ^a   Nyström, Ulla ^a   Ricksten, Anne ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Autoimmune disease; EBNA1; EBV; HUVS; Urticarial vasculitis; Viral infection

Indexed keywords

EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 1; MESSENGER RNA; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CELL PROLIFERATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN TISSUE; HYPOCOMPLEMENTEMIA; HYPOCOMPLEMENTEMIC URTICARIAL VASCULITIS SYNDROME; IMMUNE DEFICIENCY; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; URTICARIA; VASCULITIS;

ADULT; AMINO ACID SEQUENCE; ANTIBODIES, VIRAL; AUTOIMMUNITY; BASE SEQUENCE; COMPLEMENT SYSTEM PROTEINS; DNA, VIRAL; EPITOPE MAPPING; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUNG TRANSPLANTATION; MOLECULAR SEQUENCE DATA; RNA, MESSENGER; RNA, VIRAL; SYNDROME; TIME FACTORS; URTICARIA; VASCULITIS;

HUMAN HERPESVIRUS 4;

EID: 34249876930     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20893     Document Type: Article

References (23)

1. Aydogan K, Karadogan SK, Adim SB, Tunali S. 2006. Hypocomplementemic urticarial vasculitis: A rare presentation of systemic lupus erythematosus. Int J Dermatol 45:1057-1061.
2. Baer AN, McCurley T, Glick AD, Sergent JS. 1985. Evidence for immunologically mediated pulmonary injury in the hypocomplementemic urticarial vasculitis syndrome. J Am Acad Dermatol 13: 509-512.
3. Balandraud N, Roudier J, Roudier C. 2004. Epstein-Barr virus and rheumatoid arthritis. Autoimmun Rev 3:362-367.
4. Berggren MA, Isaksson A, Larsson U, Nilsson F, Nystrom U, Ekman T, Lofvenmark J, Ricksten A. 2005. Alternative EBNA1 expression in organ transplant patients. J Med Virol 76:378-385.
5. Chadburn A, Cesarman E, Knowles DM. 1997. Molecular pathology of posttransplantation lymphoproliferative disorders. Semin Diagn Pathol 14:15-26.
6. Haahr S, Hollsberg P. 2006. Multiple sclerosis is linked to Epstein-Barr virus infection. Rev Med Virol 16:297-310.
7. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. 2004. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci USA 101:239-244.
8. Inoue N, Harada S, Miyasaka N, Oya A, Yanagi K. 1991. Analysis of antibody titers to Epstein-Barr virus nuclear antigens in sera of patients with Sjogren's syndrome and with rheumatoid arthritis. J Infect Dis 164:22-28.
9. James JA, Harley JB. 1992. Linear epitope mapping of an Sm B/B′ polypeptide. J Immunol 148:2074-2079.
10. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. 1997. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 100:3019-3026.
11. Lear AL, Rowe M, Kurilla MG, Lee S, Henderson S, Kieff E, Rickinson AB. 1992. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle. J Virol 66:7461-7468.
12. McClain MT, Poolo BD, Bruner BF, Kaufman KM, Harley JB, James JA. 2006. An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum 54:360-368.
13. McDuffie FC, Sams WM, Jr, Maldonado JE, Andreini PH, Conn DL, Samayoa EA. 1973. Hypocomplementemia with cutaneous vasculitis and arthritis. Possible immune complex syndrome. Mayo Clin Proc 48:340-348.
14. Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA. 1997. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol 71:4882-4891.
15. Poole BD, Scofield RH, Harley JB, James JA. 2006. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 39:63-70.
16. Saito I, Servenius 13, Compton T, Fox RI. 1989. Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren's syndrome. J Exp Med 169:2191-2198.
17. Schwartz HR, McDuffie FC, Black LF, Schroeter AL, Conn DL. 1982. Hypocomplementemic urticarial vasculitis: Association with chronic obstructive pulmonary disease. Mayo Clin Proc 57:231-238.
18. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF. 1998. The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive. J Virol 72:7075-7083.
19. Thorley-Lawson DA. 2001. Rpstein-Barr virus: Exploiting the immune system. Nat Rev Immunol 1:75-82.
20. Thorley-Lawson DA, Gross A. 2004. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350:1328-1337.
21. Woisetschlaegor M, Yandava CN, Furmanski LA, Strominger JL, Speck SH. 1.990. Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proc Natl Acad Sci USA 87:1725-1729.
22. Yamaoka K, Miyasaka N, Yamamoto K. 1988. Possible involvement of Epstein-Barr virus in polyclonal B cell activation in Sjogren's syndrome. Arthritis Rheum 31:1014-1021.
23. Yates JL, Warren N, Sugden B. 1985. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313:812-815.